Market Access Transformation, a Genesis Research company
Tijana Ignjatovic has a diverse work experience spanning several industries. Tijana started their career as the Founder and Chief Operating Officer of Cambridge Cell Networks in 2001 and held this position until 2005. From 2005 to 2007, they worked as a Postdoctoral Research Associate at the Brain Repair Centre, University of Cambridge. In 2007, they joined Datamonitor Healthcare, Informa Plc as a Senior Analyst, Pharmaceutical Strategy Analysis Team, and later served as a Lead Analyst for Market Access. From 2018 to 2019, they worked as a Senior Director for Trends and Market Access at the same company. Most recently, Tijana has been working at Market Access Transformation since 2019, where they held roles as a Senior Consultant, Associate Director, and currently serves as the Director Ops and New Product Development Lead.
Tijana Ignjatovic completed their education with a National Baccalaureate from Peta Beogradska Gimnazija in 1995. Tijana then pursued a Bachelor of Arts degree in Natural Sciences, specializing in Biochemistry, from Trinity College at the University of Cambridge from 1996 to 1999. Tijana furthered their studies at the University of Cambridge's MRC-LMB, where they obtained their PhD in Biochemistry and Structural Biology from 1999 to 2003. Later, they pursued a Postgraduate Certificate in International HTA module of MSc in HTA, Pricing and Reimbursement at ScHARR, University of Sheffield, which they completed from 2013 to 2016.
This person is not in any teams
This person is not in any offices
Market Access Transformation, a Genesis Research company
**May 2022 Genesis Research acquired Marketing Access Transformation** Founded in 2016, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange insights that asses the real-world potential of their pharmaceutical products. With close to 65 employees that span the US, UK and India, MAT is seen as a revolutionary company in the global pharmaceutical research space. Our primary platform, Rapid Payer Responses™ (RPR), enables pharmaceutical manufacturers to conduct critical market access research throughout the product and treatment development process. Through our global, vetted payer network, it is possible to gather more accurate, robust feedback and insights by probing further and asking deeper questions. you always have the exact answers you need in a fraction of the time and cost of a traditional payer research project. Our life science experts help facilitate this process, monitoring the responses in real time as they come in for quality and detail. Since the launch of Rapid Payer Response™ (RPR) in July 2016, we have partnered with over 50 of the leading pharmaceutical manufacturers, expanded our payer network to more than 45 countries and have achieved an impressive 93% license renewal rate as we continue to disrupt the older and outdated models for payer research. Were are diverse minded, global company with offices in the US (NJ, NY & CA), UK and India. If you are interested in joining our amazing MAT team, check our openings at https://www.marketaccesstransformation.com/careers